Apellis Pharmaceuticals
APLS
APLS
92 hedge funds and large institutions have $782M invested in Apellis Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
3% less funds holding
Funds holding: 95 → 92 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
92
Holding in Top 10
3
Calls
$1.46M
Puts
$1.46M
Top Buyers
| 1 | +$75.3M | |
| 2 | +$28M | |
| 3 | +$23.2M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.5M |
| 5 |
Millennium Management
New York
|
+$14.5M |
Top Sellers
| 1 | -$17.6M | |
| 2 | -$9.58M | |
| 3 | -$8.59M | |
| 4 |
VP
venBio Partners
San Francisco,
California
|
-$5.15M |
| 5 |
NTC
NF Trinity Capital
Central,
Hong Kong
|
-$4.71M |